Two years injecting a year described as the most promising HIV virus Prevention tool In decades he is preparing to reach other millions, with new public copies at a price of $ 40 per patient annually.
Gates and Herto Labs Ltd. Glyid science It sells inc. In the United States for a list price From more than $ 28,000 annually under the brand name YEZTOGO.
The other Indian manufacturer is Dr. Reddy’s Laboratories Ltd. , To partnership with Unitaid, the Clinton Health Access, and Wits RHI to expand the offer. These moves may accelerate a global momentum to make injections available to millions of people at risk of HIV.
Despite decades of progress, HIV still represents a constant threat. I have turned the antiviral virus the virus into a controlled condition, daily Pill Allowing people to protect themselves before exposure, so far 1.3 million A new infection occurred last year. Two -thirds of those who live with HIV in Africa, where prevention tools remain rare.
Lenacapavir’s appeal lies in its durability and estimation: One injection provides protection for a period of six months, which is a special boom for women who often face obstacles to negotiating the use of condoms or delivering daily birth control pills.
“The ability to protect a person for six months with one injection, at the same cost of daily grains currently available, is truly transformer,” Bill Clinton, co -founder of the Clinton Initiative to reach health. These agreements determine “a remarkable penetration and a fundamental transformation of what is possible to prevent HIV.”
Converting this promise to reality faced great obstacles. The cost of Lenacapavir has put the injection out of the reach of women even for South African women who participated in their clinical experiences. At the same time, sweeping Discounts For US foreign aid during the era of President Donald Trump, African health systems have left to scramble to fill the gaps in financing.
For many African governments, the challenge is exacerbated by paying heavy debt that dwarfs its health budgets. Officials are forced to extend lower resources and a balance between urgent HIV needs against the competing demands for basic services.
About a year ago, Gilead Declare General Manufacturers will be allowed to start producing low -cost versions of LenacAPAVIR for 120 limited resources with high HIV. Historically, these arrangements take one or more decades of translation to widespread access, which delays the benefits of innovation for those who need them more.
Defenders say new agreements with Indian manufacturers can limit this timetable sharply. In a separate statement, Gates noticed only 18 % of people who can take advantage of preparatory currently.
She said in a statement that Gilead aims to complete the organizational introductions of LenacAPavir for Prep in 18 countries by the end of the year. Lenacapavir from the company is also expected to reach the first low -income country in this time frame.
Until the humble starting start can prevent up to 20 % of new HIV infections in high -gap countries. Public publications are expected to be distributed through national HIV programs and purchasing channels such as the World Fund, which raises hopes that the impact of injection will last for a long time.
https://fortune.com/img-assets/wp-content/uploads/2025/09/GettyImages-2233757681_73a01f-e1758717587252.jpg?resize=1200,600
Source link